7percent Ventures

7percent Ventures is a London-based deeptech-focused venture capital firm that backs ambitious founders solving large-scale global problems with frontier technology. The firm operates with a clear thesis about high-conviction, high-ambition technology investing and has built a portfolio that spans artificial intelligence, space, robotics, and emerging healthcare and biotech categories. The name itself reflects the firm’s approach to ownership and the venture math behind concentrated frontier bets.

The healthcare-relevant thesis sits inside the broader deeptech focus, with particular interest in AI applications, novel computational approaches to biology, machine learning for diagnostics and decision support, and frontier technologies that change the cost structure of care or research. The firm is comfortable with longer technical timelines and unproven category creation rather than incremental software, and tends to back technical founders with a credible scientific or engineering wedge.

Investments are at Pre-Seed and Seed with checks of roughly two hundred fifty thousand to one million dollars. Geographic focus is the United Kingdom and Europe, with selective activity in the United States and elsewhere where the firm finds founders matching its deeptech profile. 7percent often leads or co-leads at Pre-Seed and participates in larger seed rounds alongside other deeptech and frontier-focused investors.

The team is built around founder-investors with deeptech and entrepreneurship backgrounds, and operates with the conviction-driven cadence the firm’s positioning requires. Founders should expect engagement that takes their long-term vision seriously and is willing to discuss the technical and capital realities of frontier categories without flinching.

The practical value of 7percent is being one of the few credible early-stage homes for genuinely ambitious technical founders in the UK and Europe. Portfolio companies benefit from introductions across the deeptech and frontier ecosystem, follow-on investors who specialize in capital-intensive science and technology categories, and a partner that is comfortable with the long arc of building category-defining companies. The fit is strongest for technical founders building healthcare AI or computational biology products with genuine technical novelty and global ambition, and weaker for digital health or healthcare operations software companies whose problems are not fundamentally deeptech. Founders should be honest about whether their company is on the technology frontier; 7percent is built for those that are and tends to push back on positioning that overclaims technical novelty.